Literature DB >> 16556002

Evolving role of rituximab in the treatment of patients with non-Hodgkin's lymphoma.

Catherine Traullé1, Bertrand B Coiffier.   

Abstract

Rituximab is the first monoclonal antibody to have been registered for the treatment of B-cell lymphomas. Randomized studies have demonstrated its activity in follicular lymphoma, mantle cell lymphoma, and diffuse large B-cell lymphoma in untreated or relapsing patients. Rituximab has transformed the outcome of these patients because of its high activity and low toxicity. A combination of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone, has the highest efficacy ever described with any chemotherapy in diffuse large B-cell lymphoma and follicular lymphoma.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16556002     DOI： 10.1517/14796694.1.3.297

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


  10 in total

1.  Immunotherapy for Graves' orbitopathy: easy enthusiasm, but let's keep trying.

Authors:  L Bartalena; M L Tanda
Journal:  J Endocrinol Invest       Date:  2006-12       Impact factor: 4.256

2.  Primary cardiac lymphoma detected by myocardial perfusion imaging: case report.

Authors:  Biana Trost; Lori Croft; Ajith Nair; Milena Henzlova
Journal:  J Nucl Cardiol       Date:  2007-01       Impact factor: 5.952

Review 3.  Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: recent progress and applications.

Authors:  Daisuke Ito; Aric M Frantz; Jaime F Modiano
Journal:  Vet Immunol Immunopathol       Date:  2014-02-24       Impact factor: 2.046

4.  Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma.

Authors:  George O Negrea; Rebecca Elstrom; Steven L Allen; Kanti R Rai; Rashid M Abbasi; Charles M Farber; Nick Teoh; Heather Horne; William A Wegener; David M Goldenberg
Journal:  Haematologica       Date:  2010-12-20       Impact factor: 9.941

5.  Biochemical, pathological and oncological relevance of Gb3Cer receptor.

Authors:  D Đevenica; V Čikeš Čulić; A Vuica; A Markotić
Journal:  Med Oncol       Date:  2010-11-11       Impact factor: 3.064

Review 6.  2021 update on thyroid-associated ophthalmopathy.

Authors:  E J Neag; T J Smith
Journal:  J Endocrinol Invest       Date:  2021-08-20       Impact factor: 5.467

7.  Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma.

Authors:  Lawrence E Garbo; Patrick J Flynn; Margaret A MacRae; Mary A Rauch; Yunfei Wang; Kathryn S Kolibaba
Journal:  Invest New Drugs       Date:  2008-10-25       Impact factor: 3.850

8.  Development of a novel anti-canine CD20 monoclonal antibody with diagnostic and therapeutic potential.

Authors:  Daisuke Ito; Susan Brewer; Jaime F Modiano; Melissa J Beall
Journal:  Leuk Lymphoma       Date:  2014-06-16

9.  The role of autologous stem cell transplantation in the treatment of diffuse large B-cell lymphoma.

Authors:  Marco Gunnellini; Rita Emili; Stefano Coaccioli; Anna Marina Liberati
Journal:  Adv Hematol       Date:  2012-01-18

10.  Dopamine targets cycling B cells independent of receptors/transporter for oxidative attack: Implications for non-Hodgkin's lymphoma.

Authors:  Elizabeth J Meredith; Michelle J Holder; Anders Rosén; Adrian Drake Lee; Martin J S Dyer; Nicholas M Barnes; John Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-28       Impact factor: 11.205
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.